Open Orphan PLC (LON:ORPH) said a top-three global pharmaceuticals company has renewed its contract with the group's Venn Life Sciences division until the end of the year.
The team in the Breda office, in the Netherlands, will provide chemistry, manufacturing and control consultancy (CMC) services to one of the client's vaccine development programmes.
In a statement, Open Orhan chairman Cathal Friel said: "We are delighted to enter 2021 with another contract signed by the Venn team in Breda with this top-three global pharmaceutical client.
“Venn have been providing CMC support to this top tier company since 2012 and are pleased to be continuing to work with this client in their vaccine development programme.”